Regulus Therapeutics will price a public offering of its common stock

Lazard, Cowen, BMO Capital Markets, Needham, Wedbush assist with deal

By Devika Patel

Knoxville, Tenn., June 26 - Regulus Therapeutics Inc. plans to price a public offering of common stock with a 30-day greenshoe, according to a Form S-1 filed Wednesday with the Securities and Exchange Commission.

Lazard Capital Markets, Cowen and Co., BMO Capital Markets, Needham & Co. and Wedbush PacGrow Life Sciences are assisting.

Proceeds will be used for preclinical and clinical development of RG-101 and other initial microRNA development candidates, for identification and validation of additional microRNA targets and for capital expenditures, working capital and other general corporate purposes.

The biopharmaceutical company focused on drugs that target microRNAs is based in San Diego.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.